<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://vitalspanwire.com/news/older-renters-housing-isolation-mortality-study</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-23T16:02:09.706Z</news:publication_date><news:title>Older renters’ housing environment was associated with mortality risk in a 12-year study</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/nhr-49-reproductive-restraint-worm-longevity</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-23T11:02:43.711Z</news:publication_date><news:title>NHR-49 checkpoint protects lifespan by curbing reproductive resource loss in worms</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/avexitide-phase-3-post-bariatric-hypoglycemia</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-22T21:02:15.458Z</news:publication_date><news:title>Avexitide reduced severe hypoglycemia after gastric bypass in Phase 3 trial</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/fda-aletta-robotic-blood-draw-authorization</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-22T16:01:52.993Z</news:publication_date><news:title>FDA authorizes first standalone robotic blood-draw device</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/preclinical-obesity-five-year-progression</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-22T11:02:35.288Z</news:publication_date><news:title>One in three adults with ‘preclinical obesity’ progressed within five years</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/pt00114-fda-pre-ind-anxiety-trial</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-21T21:02:01.678Z</news:publication_date><news:title>Protagenic outlines U.S. trial path for neuropeptide PT00114 after FDA feedback</news:title></news:news></url></urlset>